Creating EU-CTR compliant and patient-friendly lay language summaries (LLS)
Related Insights
Blog
Breaking through complex regulations and science speak – thinking “patients first” in lay language summary development
Jun 22, 2021
Blog
BIOSECURE Act: Implications for US-based drug developers
Apr 10, 2024
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Article
New endpoints for early-stage cancer are gaining regulatory traction
Jan 28, 2022
Blog
Six steps to maximize inclusivity within medical communications | Part 1: Race and Ethnicity
Mar 3, 2022
Video
On-demand webinar: An expert guide to EU-CTR
Mar 10, 2022
Article
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
May 10, 2022
Blog
Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions
May 16, 2022
Podcast
RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry
Jun 16, 2022
Article
EU Orphan Drug Designation – overcoming regulatory challenges
Jul 20, 2022
Blog
Preparing for the New Era of Hybrid Regulatory Inspections
Jul 11, 2022
Blog
Biosimilar Development: Are therapeutic clinical trials needed?
Nov 16, 2021